Clinical Trial Update: An Open Label, Safety Study to Assess the Potential for Adrenal Suppression. [Phase 2]

View source ↗

Summary

Phase 2 open-label safety trial evaluating potential adrenal suppression risk in subjects with atopic dermatitis; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Sun Pharmaceuticals reference product

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2018-12-07